Sun Pharma’s $11.75 billion power play
In the last week of April, India Inc registered the second-largest overseas buyout after the Tata-Corus deal. India-based Sun Pharma, the world’s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products, announced a merger with NYSE-listed Organon & Co, headquartered in Jersey City, New Jersey.
On 26 April 2026, the company announced that it had entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion.
For starters, Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside the US and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across women’s health and general medicines, including biosimilars, commercialised across 140 countries, with the US, Europe, China, Canada and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach.
Together, Organon’s general medicines and women’s health franchise reflect the company’s commitment to advancing access and affordability for communities around the world.
The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its innovative medicines business. The combined entity will become a stronger player in the established brands/branded generics business. The deal also enables Sun Pharma’s entry into biosimilars as a top-10 global player. Organon’s portfolio, global footprint and strong stakeholder relationships will complement Sun Pharma’s existing strengths and enhance long-term value creation.
Sun Pharma’s innovative medicines portfolio spans products in dermatology, ophthalmology and oncodermatology, and accounts for about 20 per cent of company sales. The company’s vertically integrated operations deliver high-quality medicines trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations.
In the top league
What does this transaction mean in terms of ranking? The consummation of the transaction makes Sun Pharma one of the top 25 global pharmaceutical companies, with combined revenue of $12.4 billion. It also positions Sun Pharma as a more innovative medicines-focused company, with a 27 per cent revenue share, and among the top three in global women’s health, creating a commercial platform for future growth. It will also rank as the seventh-largest global biosimilar player, with a presence in 150 countries, including 18 large markets each generating over $100 million in revenue. The company will have a stronger cash-generating profile, with EBITDA and cash flow set to nearly double, supporting deleveraging from post-transaction Net Debt/EBITDA of 2.3x.
“This transaction represents a significant opportunity for Sun Pharma to build on its vision of ‘Reaching People and Touching Lives’. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organisations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long-term growth,” explains Dilip Shanghvi, Executive Chairman of Sun Pharma.
Adds Kirti Ganorkar, MD of Sun Pharma: “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon’s talent pool. In addition, there is scope for synergies, including significant revenue upside opportunities to be realised over the coming years.”
Carrie Cox, Executive Chair of Organon, commented: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions.”
Transaction summary: Sun Pharma will acquire 100 per cent of Organon’s issued and outstanding shares for cash. Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. The transaction is expected to close in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval.
Financially, for the year ended 31 December 2025, Organon reported $6.2 billion in revenue and adjusted EBITDA of $1.9 billion. Organon had debt of $8.6 billion and a cash balance of $574 million. Organon recently completed a divestiture of a product for which it received an upfront payment of $440 million, the net proceeds of which will further contribute to its 31 March 2026 cash balance.
Inorganic growth
Ever since 2010, Shanghvi has specialised in M&As with a clear strategy and rationale. To begin with, the acquisition of Taro Pharmaceutical Industries (Israel/USA) was completed in 2010 at a deal value of over $400 million, in a bid to access its dermatology generics portfolio and manufacturing facilities in Israel and Canada. Then, in 2012, Sun Pharma acquired DUSA Pharmaceuticals for $230 million to gain access to American specialty drug-device combinations in the dermatology segment.
Four years later, it entered the Japanese market. Sun made a $293 million deal by acquiring Novartis’ Japanese brands of more than a dozen drugs. Then, in 2014, through a $4 billion all-stock merger, it acquired Ranbaxy Laboratories (India), which strengthened its position in the global generic pharma industry, making it the number one pharma company in India and giving it a strong position in emerging markets.
In the last 3 years, Sun brought Concert Pharmaceuticals under its fold at a deal value of $576 million through an upfront cash payment, adding a late-stage specialty product to its dermatology franchise and treatment portfolio for alopecia areata.
In the US, in 2025, it acquired Checkpoint Therapeutics for $355 million for its first and only US FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC). And now comes the Organon acquisition at $11.75 billion in an all-cash deal.
The recent acquisition has drawn attention from the bourses. On the BSE, the share traded at Rs1,691 (24 April 2026) on the eve of the announcement and is now (30 April 2026) changing hands at Rs1,808, up 8 per cent. “At an EV of $11.75 billion (Rs98,000 crore) at $14/share (24 per cent premium), adding $6.2 billion revenue and $1.9 billion EBITDA (30 per cent margins), and taking pro forma combined revenue to $12.4 billion (2x scale), the deal will be largely debt-funded, with Sun assuming $8.6 billion net debt, pushing leverage to 2.3x net debt/EBITDA, but expected to be 30-40 per cent EPS accretive by FY28. Markets are reacting positively (stock up 7-9 per cent) because investors are pricing in a scale jump, entry into high-margin specialty segments (women’s health/biosimilars), and strong cash-flow visibility, despite near-term concerns around leverage and integration execution,” Sunil Pachisia, Director, Pratibhuti Vinihit Ltd, Member NSE - Institutional Equity Broking, explaining the market response.
“The rally in Sun Pharmaceutical Industries reflects three things investors like: a scale jump (revenue nearly doubling to $12 billion), the margin profile (Organon brings 30 per cent EBITDA, lifting blended profitability), and a portfolio shift towards higher-value segments like women’s health and biosimilars via Organon & Co. Expected 30-40 per cent EPS accretion by FY28 signals strong earnings visibility despite the large size of the deal,” adds Pachisia, recommending a ‘buy’.
“We are optimistic on the deal. We retain our Buy rating on the stock. Any significant post-announcement dip presents a compelling buying opportunity. The valuation works out to 6.2x trailing EV/EBITDA, which is reasonable in our view, given the lack of growth in Organon’s business. Further, we expect Sun to significantly enhance operating efficiency and derive additional value from the acquisition. It is a strategic move to enter newer therapy areas within branded generics in women’s health and biosimilars – two areas where Sun is not present. These segments face lower competition in fast-growing markets compared to the regular generics business in regulated markets. In addition, Sun’s penetration into select large markets such as China and South Korea will improve. Funding through both cash and debt: Sun will fund the acquisition through a combination of cash on books and debt from banks. As of H1 FY26, Sun had $3 billion cash on books at the consolidated level. Sun expects post-transaction consolidated net debt/EBITDA of 2.3x, which is within manageable limits in our view,” states Bino Pathiparampil, healthcare and pharmaceuticals strategist at Elara Capital, who sees the transaction as a step change in Sun’s long-term strategy, accelerating its transition towards a globally diversified, innovation-driven pharmaceutical company.
“Organon brings an $800 million-plus China business, a scaled EU commercial front end, and presence in South Korea, Mexico and Thailand, where Sun had limited or no direct operations. It also brings a 4,000-strong field force across these markets that Sun can use to cross-sell its own products, particularly Ilumya (which was originally developed in Organon’s labs and has not been commercialised in Korea),” states a Nirmal Bang institutional report.
Pipeline of molecules
Sun Pharma has a few new molecules in the pipeline, currently at Phase 2, Phase 3 and near registration stages. To name a few: Ilumya (psoriatic arthritis), Fibromun (soft tissue sarcoma and glioblastoma) and Nidlegy (locally advanced cSCC), alongside others under partnership. Internationally, this could place the company in the big league, competing with major global pharmaceutical companies. “They are now big enough to enter that field to compete with GSK and AstraZeneca in the UK, leaving aside the real US biggies such as Pfizer, J&J and Eli Lilly,” says Pachisia.
Nonetheless, China remains a significant risk. The company is still dependent on China for APIs, the building blocks of the generic industry. China could potentially disrupt supplies in the future. The company remains silent on this critical issue.